Status:

COMPLETED

Clinical Study of Asahi ViE Dialyzer in Canada

Lead Sponsor:

Asahi Kasei Medical Co., Ltd.

Conditions:

Kidney Failure, Chronic

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The purpose of the study is to obtain performance data on the Asahi ViE-21 dialyzer (ViE-21) .

Detailed Description

The objective of the study is to evaluate specific parameters related to ViE-21 performance including (A) Performance evaluated by uremic solute removal rates of urea, creatinine, albumin and B2-MG, (...

Eligibility Criteria

Inclusion

  • Patients ≥ 18 years and ≤ 80 years of age
  • Stable on maintenance hemodialysis for at least 12 weeks
  • Patients expected to remain on hemodialysis for at least 24 weeks
  • Patients on hemodialysis for more than 3 hours per treatment and on a 3 times per week schedule
  • Patients whose vascular access is obtained via arteriovenous fistula or graft, is well maintained and is capable of obtaining blood flow rate ≥ 350 mL/min during the study period
  • Patients using high-flux dialyzers (KUF ≥ 40 mL/hr/mmHg) with surface area ≥ 1.5 square meters and ≤ 2.2 square meters
  • Patients capable of understanding the informed consent form
  • Written consent and willingness to participate in the study

Exclusion

  • Medical conditions requiring regular blood transfusion
  • Patients with a history of more than one week hospitalization related to infection, inflammation or surgery within the past 12 weeks
  • Patients having participated in another clinical investigation within the past 12 weeks, currently participating or having a plan of participating in any other clinical investigation (patients in an observational study without any interventions or in post-market surveillance do not need to be excluded)
  • Patients who have difficulty in maintaining vascular access function within the past 12 weeks
  • Patients who are known to be hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) positive
  • Female patients who are pregnant, breast feeding or planning a pregnancy within the study period
  • Patients having received blood purification therapy other than conventional dialysis within the past 12 weeks
  • Patients who cannot tolerate Heparin
  • Any serious medical, social or psychological condition that in the opinion of the investigator would disqualify a patient from participation

Key Trial Info

Start Date :

November 24 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 6 2015

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT02292212

Start Date

November 24 2014

End Date

November 6 2015

Last Update

December 11 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.